Here are four things to know.
1. The treatment is a combination of Verzenio, an already FDA-approved medication, and an aromatase inhibitor.
2. It is approved for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
3. The approval is the third expanded approval for Verzenio in the last five months.
4. “This approval is an important milestone, as it shows that Verzenio plus an aromatase inhibitor substantially reduced tumor size and delayed disease progression in women with HR+, HER2- metastatic breast cancer,” Eli Lilly said in a press release.
More articles on supply chain:
Why a better hospital supply chain starts with better relationships
Teva shutters offices in New York City, Washington D.C., as part of cost cutting plan
Walgreens, AmerisourceBergen reportedly end takeover discussions with no deal
